Bone Biologics Corp (BBLG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bone Biologics Corporation on December 22, 2021, reporting events occurring on December 17, 2021. The Company is incorporated in Delaware and its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols BBLG and BBLGW, respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a material definitive agreement regarding executive compensation.
Material Changes and Agreements
On December 17, 2021, the Company entered into a revised Employment Agreement with Deina H. Walsh, its Chief Financial Officer (CFO) and principal accounting officer, effective January 3, 2022. Key terms include:
- Employment Status: At-will employment with no specified term; terminable at any time with or without cause.
- Base Salary: $200,000 annually.
- Annual Bonus: Target bonus of 25% of base salary, contingent on personal and corporate objectives established by the Board. Payment is due by March 15 of the following year.
- Equity Grant: Option to purchase 25,000 shares of Common Stock at the current market price on the grant date. Options have a two-year maturity and are forfeited upon termination unless the termination is without cause or results from a Change in Control.
- Anti-Dilution: Ms. Walsh is granted the opportunity to invest in future financings to maintain her equity interest undiluted or partially diluted.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, or specific risk factors beyond the standard terms of the employment agreement. The agreement notes that bonus achievement depends on objectives set by the Board.
Investor Verification Checklist
- Verify the full text of the Employment Agreement attached as Exhibit 10.1 for complete legal terms.
- Confirm the specific corporate and personal objectives required to earn the 25% target bonus.
- Monitor the Company's future financing activities to assess the execution of the anti-dilution provision for the CFO.
- Review subsequent filings for the actual grant date and exercise price of the 25,000 stock options.